PJP Fact Sheet: Invesco Pharmaceuticals ETF
Share
$128.23
close, Nov 18, 2026
Over the year to Nov 18, 2026, PJP returned +24.4% in total and charged 0.58% a year.
- 1-year total return
- +24.4%
- to Nov 18, 2026
- Expense ratio
- 0.58%
- a year
- Net assets
- $602m
- on Nov 17, 2026
- Net flow, last 5 trading days
- +$5.2m
- daily basis to Nov 17, 2026
Growth of $10,000, 1 year
PJP $12,439 +24.4% · IVV $11,186 +11.9% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.
Returns
WindowTotal return
1 month+3.8%
3 months−2.4%
Year to date+23.6%
1 year+24.4%
3 years+89.2%
5 years+68.0%
Total return, distributions reinvested, each window to Nov 18, 2026.
Ten largest positions
HoldingWeight
Eli Lilly & Co6.18%
Gilead Sciences Inc6.16%
AbbVie Inc5.93%
Amgen Inc5.56%
Johnson & Johnson5.49%
Pfizer Inc5.44%
Merck & Co Inc4.93%
Abbott Laboratories4.84%
Viatris Inc3.75%
Amneal Pharmaceuticals Inc3.61%
PJP top ten by weight, 51.9% of the fund, of its 31 equity positions, from the holdings published by its issuer for Nov 17, 2026.
Facts
Equity fund · Tracks the Dynamic Pharmaceutical Intellidex Index · First traded Jun 23, 2005 · Benchmark Its own holdings, as of Nov 17, 2026